Malaria is one of the most devastating tropical diseases despite the availability of numerous drugs acting against the protozoan parasite Plasmodium in its human host. However, the development of drug resistance renders most of the existing drugs useless. In the malaria parasite the tripeptide glutathione is not only involved in maintaining an adequate intracellular redox environment and protecting the cell against oxidative stress, but it has also been shown that it degrades non-polymerized ferriprotoporphyrin IX (FP IX) and is thus implicated in the development of chloroquine resistance. Glutathione levels in Plasmodium-infected red blood cells are regulated by glutathione synthesis, glutathione reduction and glutathione efflux. Therefore the effects of drugs that interfere with these metabolic processes were studied to establish possible differences in the regulation of the glutathione metabolism of a chloroquine-sensitive and a chloroquine-resistant strain of Plasmodiumfalciparum. Growth inhibition of P. falciparum 3D7 by d,l-buthionine-(S,R)sulphoximine (BSO), an inhibitor of γ-glutamylcysteine synthetase (γ-GCS), and by Methylene Blue (MB), an inhibitor of gluta thione reductase (GR), was significantly more pronounced than inhibition of P.falciparum Dd2 growth by these drugs. These results correlate with the higher levels of total glutathione in P. falciparum Dd2. Short-term incubations of Percoll-enriched trophozoite-infected red blood cells in the presence of BSO, MB and N,N1-bis(2-chloroethyl)-N-nitrosourea and subsequent determinations of γ-GCS activities, GR activities and glutathione disulphide efflux revealed that maintenance of intracellular glutathione in P. falciparum Dd2 is mainly dependent on glutathione synthesis whereas in P. falciparum 3D7 it is regulated via GR. Generally, P. falciparum Dd2 appears to be able to sustain its intracellular glutathione more efficiently than P. falciparum 3D7. In agreement with these findings is the differential susceptibility to oxidative stress of both parasite strains elicited by the glucose/glucose oxidase system.
Skip Nav Destination
Close
Article navigation
December 2002
- PDF Icon PDF LinkFront Matter
Research Article|
December 15 2002
Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum
Svenja MEIERJOHANN
;
Svenja MEIERJOHANN
∗Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany,
Search for other works by this author on:
Rolf D. WALTER
;
Rolf D. WALTER
∗Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany,
Search for other works by this author on:
Sylke MÜLLER
Sylke MÜLLER
1
∗Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany,
†Division of Biological Chemistry and Molecular Microbiology, School of Life Sciences, University of Dundee, MSI/WTB Complex, Dundee DD1 5EH, U.K.
1To whom correspondence should be addressed, at the University of Dundee (e-mail s.muller@dundee.ac.uk).
Search for other works by this author on:
Biochem J (2002) 368 (3): 761–768.
Article history
Received:
June 24 2002
Revision Received:
September 03 2002
Accepted:
September 12 2002
Accepted Manuscript online:
September 12 2002
Citation
Svenja MEIERJOHANN, Rolf D. WALTER, Sylke MÜLLER; Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochem J 15 December 2002; 368 (3): 761–768. doi: https://doi.org/10.1042/bj20020962
Download citation file:
Close
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Related Articles
Extracellular matrix regulation of drug resistance in small-cell lung cancer
Clin Sci (Lond) (March,2002)
Reversal of EGFR inhibitors’ resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer
Biosci Rep (August,2019)